Sequent Scientific 過去の業績
過去 基準チェック /36
Sequent Scientificの収益は年間平均-54.3%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間13.4% 3.9%割合で 増加しています。 Sequent Scientificの自己資本利益率は3.7%であり、純利益率は1.1%です。
主要情報
-54.3%
収益成長率
-54.6%
EPS成長率
| Pharmaceuticals 業界の成長 | 17.5% |
| 収益成長率 | 3.9% |
| 株主資本利益率 | 3.7% |
| ネット・マージン | 1.1% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt
Sep 27
What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You
Sep 05Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT)
Apr 05Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet
Mar 10Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified?
Jan 31How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year?
Jan 17Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play?
Jan 05What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)?
Dec 24Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock?
Dec 12
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly
Nov 22Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT)
Nov 10The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It
Oct 20How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance?
Oct 05収支内訳
収支内訳
Sequent Scientific の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 14,494 | 165 | 2,534 | 0 |
| 30 Jun 24 | 14,267 | 55 | 2,485 | 0 |
| 31 Mar 24 | 13,697 | -359 | 2,549 | 0 |
| 31 Dec 23 | 13,705 | -1,285 | 2,565 | 0 |
| 30 Sep 23 | 14,212 | -1,457 | 2,655 | 0 |
| 30 Jun 23 | 14,128 | -1,410 | 2,616 | 0 |
| 31 Mar 23 | 14,209 | -1,212 | 2,620 | 0 |
| 31 Dec 22 | 14,380 | -186 | 2,533 | 0 |
| 30 Sep 22 | 14,207 | 74 | 2,327 | 0 |
| 30 Jun 22 | 14,336 | 263 | 2,302 | 0 |
| 31 Mar 22 | 14,128 | 410 | 2,337 | 0 |
| 31 Dec 21 | 13,909 | 529 | 2,322 | 0 |
| 30 Sep 21 | 13,879 | 713 | 2,317 | 0 |
| 30 Jun 21 | 13,869 | 805 | 2,087 | 0 |
| 31 Mar 21 | 13,616 | 954 | 1,913 | 0 |
| 31 Dec 20 | 13,153 | 963 | 1,782 | 0 |
| 30 Sep 20 | 12,735 | 793 | 1,751 | 0 |
| 30 Jun 20 | 12,115 | 794 | 1,695 | 0 |
| 31 Mar 20 | 11,792 | 699 | 1,682 | 0 |
| 31 Dec 19 | 11,606 | 702 | 1,730 | 0 |
| 30 Sep 19 | 11,147 | 629 | 1,670 | 0 |
| 30 Jun 19 | 10,822 | 568 | 1,505 | 0 |
| 31 Mar 19 | 10,393 | 487 | 1,561 | 0 |
| 31 Dec 18 | 9,902 | 348 | 1,479 | 0 |
| 30 Sep 18 | 9,446 | 160 | 1,410 | 0 |
| 30 Jun 18 | 8,904 | 36 | 1,346 | 0 |
| 31 Mar 18 | 8,478 | 9 | 1,227 | 0 |
| 31 Dec 17 | 10,457 | 204 | 1,437 | 0 |
| 30 Sep 17 | 10,302 | 352 | 1,447 | 0 |
| 30 Jun 17 | 9,914 | 184 | 1,356 | 0 |
| 31 Mar 17 | 6,836 | -113 | 1,150 | 0 |
| 31 Dec 16 | 8,797 | -349 | 1,374 | 0 |
| 30 Sep 16 | 7,592 | -430 | 1,213 | 0 |
| 30 Jun 16 | 6,652 | -325 | 991 | 0 |
| 31 Mar 16 | 6,062 | -200 | 904 | 0 |
| 31 Dec 15 | 5,718 | -848 | 1,333 | 0 |
| 30 Sep 15 | 5,297 | -848 | 1,256 | 0 |
| 30 Jun 15 | 4,789 | -535 | 1,236 | 0 |
| 31 Mar 15 | 4,432 | -657 | 634 | 0 |
| 31 Dec 14 | 3,779 | -676 | 579 | 0 |
| 30 Sep 14 | 3,805 | -714 | 529 | 0 |
| 30 Jun 14 | 4,467 | -1,125 | 468 | 0 |
| 31 Mar 14 | 3,950 | -1,103 | 896 | 0 |
質の高い収益: SEQUENTは 高品質の収益 を持っています。
利益率の向上: SEQUENT過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: SEQUENT過去 5 年間で収益を上げており、収益は年間-54.3%増加しています。
成長の加速: SEQUENTは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: SEQUENT昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 20% ) と比較することは困難です。
株主資本利益率
高いROE: SEQUENTの 自己資本利益率 ( 3.7% ) は 低い とみなされます。